Cargando…

The ruthenium compound KP1339 potentiates the anticancer activity of sorafenib in vitro and in vivo()

KP1339 is a promising ruthenium-based anticancer compound in early clinical development. This study aimed to test the effects of KP1339 on the in vitro and in vivo activity of the multi-kinase inhibitor sorafenib, the current standard first-line therapy for advanced hepatoma. Anticancer activity of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Heffeter, Petra, Atil, Bihter, Kryeziu, Kushtrim, Groza, Diana, Koellensperger, Gunda, Körner, Wilfried, Jungwirth, Ute, Mohr, Thomas, Keppler, Bernhard K., Berger, Walter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Science Ltd 2013
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3807657/ https://www.ncbi.nlm.nih.gov/pubmed/23790465 http://dx.doi.org/10.1016/j.ejca.2013.05.018

Ejemplares similares

Interaction with Ribosomal Proteins Accompanies Stress Induction of the Anticancer Metallodrug BOLD‐100/KP1339 in the Endoplasmic Reticulum
por: Neuditschko, Benjamin, et al.
Publicado: (2021)

Serum-binding properties of isosteric ruthenium and osmium anticancer agents elucidated by SEC–ICP–MS
por: Klose, Matthias H. M., et al.
Publicado: (2018)

NAMI-A and KP1019/1339, Two Iconic Ruthenium Anticancer Drug Candidates Face-to-Face: A Case Story in Medicinal Inorganic Chemistry
por: Alessio, Enzo, et al.
Publicado: (2019)

The Anticancer Ruthenium Compound BOLD-100 Targets Glycolysis and Generates a Metabolic Vulnerability towards Glucose Deprivation
por: Baier, Dina, et al.
Publicado: (2022)

NKP-1339, a first-in-class anticancer drug showing mild side effects and activity in patients suffering from advanced refractory cancer
por: Trondl, Robert, et al.
Publicado: (2012)

An albumin-based tumor-targeted oxaliplatin prodrug with distinctly improved anticancer activity in vivo
por: Mayr, Josef, et al.
Publicado: (2017)

Impact of terminal dimethylation on the resistance profile of α-N-heterocyclic thiosemicarbazones
por: Heffeter, Petra, et al.
Publicado: (2012)

DMSO reduces the cytotoxicity of anticancer ruthenium complex KP1019 in yeast
por: Davis, Jonathan, et al.
Publicado: (2021)

Chronic arsenic trioxide exposure leads to enhanced aggressiveness via Met oncogene addiction in cancer cells
por: Kryeziu, Kushtrim, et al.
Publicado: (2016)

Human serum albumin as a copper source for anticancer thiosemicarbazones
por: Schaier, Martin, et al.
Publicado: (2023)

Inhibitory Effects of the Ruthenium Complex KP1019 in Models of Mammary Cancer Cell Migration and Invasion
por: Bergamo, A., et al.
Publicado: (2009)

Electronic State of Sodium trans-[Tetrachloridobis(1H-indazole)ruthenate(III)] (NKP-1339) in Tumor, Liver and Kidney Tissue of a SW480-bearing Mouse
por: Blazevic, Amir, et al.
Publicado: (2017)

Molecular mode of action of NKP-1339 – a clinically investigated ruthenium-based drug – involves ER- and ROS-related effects in colon carcinoma cell lines
por: Flocke, Lea S., et al.
Publicado: (2016)

Distinct activity of the bone-targeted gallium compound KP46 against osteosarcoma cells - synergism with autophagy inhibition
por: Kubista, Bernd, et al.
Publicado: (2017)

Water-Soluble, Biocompatible Polyphosphazenes with Controllable and pH-Promoted Degradation Behavior
por: Wilfert, Sandra, et al.
Publicado: (2014)

Albumin-targeting of an oxaliplatin-releasing platinum(iv) prodrug results in pronounced anticancer activity due to endocytotic drug uptake in vivo
por: Schueffl, Hemma, et al.
Publicado: (2021)

The Lipid Metabolism as Target and Modulator of BOLD‐100 Anticancer Activity: Crosstalk with Histone Acetylation
por: Baier, Dina, et al.
Publicado: (2023)

Comparison of metabolic pathways of different α-N-heterocyclic thiosemicarbazones
por: Pelivan, Karla, et al.
Publicado: (2018)

AGREEMENT CERN No. K 1339
por: The European Organisation for Nuclear Research, CERN, et al.
Publicado: (2006)

Metal–Arene Complexes with Indolo[3,2-c]-quinolines: Effects of Ruthenium vs Osmium and Modifications of the Lactam Unit on Intermolecular Interactions, Anticancer Activity, Cell Cycle, and Cellular Accumulation
por: Filak, Lukas K., et al.
Publicado: (2013)

X-ray Absorption Near Edge Structure Spectroscopy to Resolve the in Vivo Chemistry of the Redox-Active Indazolium trans-[Tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019)
por: Hummer, Alfred A., et al.
Publicado: (2013)

Tumor-targeted dual-action NSAID-platinum(iv) anticancer prodrugs
por: Kastner, Alexander, et al.
Publicado: (2023)

ACCELERATION OF HEPATIC CHOLESTEROL SYNTHESIS BY TRITON WR-1339
por: Frantz, Ivan D., et al.
Publicado: (1955)

THE MECHANISM RESPONSIBLE FOR THE HYPERCHOLESTEREMIA INDUCED BY TRITON WR-1339
por: Friedman, Meyer, et al.
Publicado: (1953)

Liposomal formulations of anticancer copper(ii) thiosemicarbazone complexes
por: Mathuber, Marlene, et al.
Publicado: (2021)

X-ray Structure Analysis of Indazolium trans-[Tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019) Bound to Human Serum Albumin Reveals Two Ruthenium Binding Sites and Provides Insights into the Drug Binding Mechanism
por: Bijelic, Aleksandar, et al.
Publicado: (2016)

Pharmacy students’ knowledge and attitudes about antibiotics in Kosovo
por: Fejza, Albina, et al.
Publicado: (2016)

Influence of the π-coordinated arene on the anticancer activity of ruthenium(II) carbohydrate organometallic complexes
por: Hanif, Muhammad, et al.
Publicado: (2013)

Single Spheroid Metabolomics: Optimizing Sample Preparation of Three-Dimensional Multicellular Tumor Spheroids
por: Rusz, Mate, et al.
Publicado: (2019)

Physicochemical Studies and Anticancer Potency of Ruthenium η(6)-p-Cymene Complexes Containing Antibacterial Quinolones
por: Kljun, Jakob, et al.
Publicado: (2011)

Anticancer Ruthenium Complexes with HDAC Isoform Selectivity
por: Cross, Jasmine M., et al.
Publicado: (2020)

Arene Variation of Highly Cytotoxic Tridentate Naphthoquinone-Based Ruthenium(II) Complexes and In-Depth In Vitro Studies
por: Cseh, Klaudia, et al.
Publicado: (2022)

Thermodynamic Genome-Scale Metabolic Modeling of Metallodrug Resistance in Colorectal Cancer
por: Herrmann, Helena A., et al.
Publicado: (2021)

In vitro and in vivo downregulation of the ATP binding cassette transporter B1 by the HMG-CoA reductase inhibitor simvastatin
por: Atil, Bihter, et al.
Publicado: (2015)

Structure–Activity Relationships of Triple-Action Platinum(IV) Prodrugs with Albumin-Binding Properties and Immunomodulating Ligands
por: Fronik, Philipp, et al.
Publicado: (2021)

Statins modulate the expression profile of ATP-binding cassette transporters in human neuroblastoma cells
por: Atil, Bihter, et al.
Publicado: (2011)

Statins reduce endogenous dolichol levels in the neuroblastoma cell line SH-SY5Y
por: Atil, Bihter, et al.
Publicado: (2012)

Mechanistic insights into the more potent effect of KP-54 compared to KP-10 in vivo
por: d'Anglemont de Tassigny, Xavier, et al.
Publicado: (2017)

Influence of ICRF 159 and trition WR 1339 on metastases of a rat epithelioma.
por: Pimm, M. V., et al.
Publicado: (1975)

1339. Effects of Tixagevimab-Cilgavimab in Clinical Practice is Consistent with Preliminary Neutralization Studies
por: Dluzynski, Daniela, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vnigqeksb00i5thr0tuodeme8q